A detailed history of Huntington National Bank transactions in Uni Qure N.V. stock. As of the latest transaction made, Huntington National Bank holds 2 shares of QURE stock, worth $11. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2
Previous 2 -0.0%
Holding current value
$11
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 10, 2022

SELL
$14.54 - $21.5 $3,998 - $5,912
-275 Reduced 99.28%
2 $0
Q4 2021

Jan 21, 2022

SELL
$20.24 - $36.01 $2,712 - $4,825
-134 Reduced 32.6%
277 $6,000
Q2 2021

Jul 30, 2021

BUY
$29.97 - $37.17 $3,776 - $4,683
126 Added 44.21%
411 $13,000
Q1 2021

Apr 12, 2021

SELL
$29.24 - $42.03 $847 - $1,218
-29 Reduced 9.24%
285 $10,000
Q4 2020

Jan 11, 2021

SELL
$35.35 - $50.67 $212 - $304
-6 Reduced 1.88%
314 $11,000
Q3 2020

Oct 30, 2020

BUY
$35.98 - $47.66 $11,513 - $15,251
320 New
320 $12,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Huntington National Bank Portfolio

Follow Huntington National Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Huntington National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Huntington National Bank with notifications on news.